Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Mani S, Kugler JW, Sciortino DF, Garcia JC, Ansari RH, Humerickhouse R, Michelassi F, Posner MC, Shulman KL, Schilsky RL, List M, Vokes EE, Benner S. Mani S, et al. Among authors: schilsky rl. Ann Oncol. 1998 Sep;9(9):1035-7. doi: 10.1023/A:1008427231049. Ann Oncol. 1998. PMID: 9818081 Free article. Clinical Trial.
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohneker J, Schilsky RL, Lokich J. Mani S, et al. Among authors: schilsky rl. J Clin Oncol. 2000 Aug;18(15):2894-901. doi: 10.1200/JCO.2000.18.15.2894. J Clin Oncol. 2000. PMID: 10920138 Clinical Trial.
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, Ansari RH, Bell WN, White RL, Yates BB, McGuirt PV, Pazdur R. Schilsky RL, et al. J Clin Oncol. 2002 Mar 15;20(6):1519-26. doi: 10.1200/JCO.2002.20.6.1519. J Clin Oncol. 2002. PMID: 11896100 Clinical Trial.
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. Rini BI, et al. Among authors: schilsky rl. Clin Cancer Res. 2004 Apr 15;10(8):2584-6. doi: 10.1158/1078-0432.ccr-03-0605. Clin Cancer Res. 2004. PMID: 15102658 Clinical Trial.
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. Ellis LM, et al. Among authors: schilsky rl. J Clin Oncol. 2014 Apr 20;32(12):1277-80. doi: 10.1200/JCO.2013.53.8009. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24638016 No abstract available.
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL. Mangat PK, et al. Among authors: schilsky rl. JCO Precis Oncol. 2018;2018:10.1200/PO.18.00122. doi: 10.1200/PO.18.00122. Epub 2018 Jul 11. JCO Precis Oncol. 2018. PMID: 30603737 Free PMC article.
376 results